247,012 Shares in Kenvue Inc. $KVUE Bought by Sanctuary Advisors LLC

Sanctuary Advisors LLC purchased a new stake in shares of Kenvue Inc. (NYSE:KVUE) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 247,012 shares of the company’s stock, valued at approximately $4,720,000.

A number of other institutional investors have also bought and sold shares of the company. Johnson Financial Group Inc. bought a new stake in shares of Kenvue during the 2nd quarter valued at about $26,000. CoreCap Advisors LLC grew its stake in Kenvue by 64.9% during the second quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock worth $29,000 after purchasing an additional 591 shares during the period. Elyxium Wealth LLC bought a new stake in Kenvue in the fourth quarter worth approximately $26,000. Physician Wealth Advisors Inc. increased its holdings in Kenvue by 67.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after purchasing an additional 618 shares in the last quarter. Finally, MV Capital Management Inc. acquired a new position in Kenvue in the fourth quarter valued at approximately $28,000. Institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Barclays increased their price target on Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 21st. UBS Group lowered their price objective on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research note on Tuesday, August 11th. Zacks Research downgraded shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Weiss Ratings raised shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 15th. Finally, Wall Street Zen cut shares of Kenvue from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Three equities research analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $19.27.

Kenvue Stock Up 1.8%

Shares of NYSE:KVUE opened at $19.41 on Tuesday. The business’s 50 day simple moving average is $19.08 and its two-hundred day simple moving average is $18.21. The firm has a market cap of $37.27 billion, a P/E ratio of 22.30, a PEG ratio of 1.36 and a beta of 0.47. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.71 and a current ratio of 1.01. Kenvue Inc. has a 52-week low of $14.02 and a 52-week high of $21.63.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.31 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.01). Kenvue had a return on equity of 21.22% and a net margin of 10.76%.The business had revenue of $3.96 billion for the quarter, compared to analyst estimates of $3.97 billion. During the same quarter in the previous year, the company posted $0.29 EPS. The business’s quarterly revenue was up 3.0% on a year-over-year basis. As a group, research analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, August 26th. Stockholders of record on Wednesday, August 12th will be paid a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a dividend yield of 4.3%. The ex-dividend date is Wednesday, August 12th. This is a boost from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s dividend payout ratio (DPR) is presently 96.55%.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over?the?counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.